On February 1, NEJM, the top medical journal, published the results of a pivotal multi-center critical phase 2 trial in support of the “first CAR-T therapy Tisagenlecleucel listed”. The overall survival of patientsRead More…
CAR T Cells Manufacture Upgrades
Chimeric antigen receptor, or CAR, T cells have considerably improved cancer treatment outcomes for certain malignancies. CAR T cells are produced when T cells isolated from the patient are modified to targetRead More…
What Is Mesothelin?
As we all know, CD19 is the most frequently used target marker for CAR-T cell therapy clinical trials. But not much people knows about the second frequently used target biomarker is mesothelin. What’s more,Read More…
What Is CD19 Antigen?
As the data from clinicaltrials.gov shows, CD19 antigen is the most frequently used biomarker in CAR-T cell therapy clinical trials for hematological malignancy such as leukemia and lymphoma. According to our statistics report, overRead More…
What the Next Generation T Cell Therapy Looks Like
T cell receptors (TCRs) provide a recognition signal for T cells complemented by a co-stimulatory signal that can provide an on/off signal to regulate the activation of T cells. Since Medawar andRead More…
What Is the Important Role of the Transmembrane Spacer Domain in CAR Design?
As we know, a typical design of 2rd generation Chimeric antigen receptor contains 3 functional units: a recognition domain, a transmembrane spacer domain and an intracellular signal transduction domain. Antigen recognition domainRead More…
Literature Reading: Driving Gene-engineered T Cell Immunotherapy of Cancer
This is a review article published on Cell Research (2017) 27: 38-58 by Laura A Johnson and Carl H June. Dr. Carl H. June is the director of translational research at the Abramson Cancer CenterRead More…
The Latest Developments in CAR-T Research
CAR-T, Chimeric Antigen Receptor T Cell Immunotherapy, is a new cell therapy that has been developed for many years but has only been improved in recent years. Considered as one of the most promisingRead More…
Latest Research Results on CAR-T Therapy reveal a possible reason of CAR-T neurotoxicity
There is no doubt that this year marks the beginning of CAR-T therapy owing to the advent of two CAR-T therapies and the changes that these therapies have brought to the lives ofRead More…
FDA approval brings first gene therapy to the United States…
“First CAR T-cell Therapy – Kymriah created from Novartis was approved by the FDA in August 2017. Two months later, Yescarta developed by Kite Pharma, Inc) is the second gene therapy approvedRead More…